FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Little Ones Petroleum Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
FOR EXTERNAL USE ONLY
DO NOT GET INTO EYES
CONDITIONS LASTS MORE THAN 7 DAYS
- DEEP PUNCTURE WOUNDS
- ANIMAL BITES
- SERIOUS BURNS
IF SWALLOWED, GET MEDICAL HELP OR CONTACT A POISON CONTROL CENTER RIGHT AWAY. 1-800-222-1222
CONDITIONS LASTS MORE THAN 7 DAYS
- DEEP PUNCTURE WOUNDS
- ANIMAL BITES
- SERIOUS BURNS
IF SWALLOWED, GET MEDICAL HELP OR CONTACT A POISON CONTROL CENTER RIGHT AWAY. 1-800-222-1222
- DEEP PUNCTURE WOUNDS
- ANIMAL BITES
- SERIOUS BURNS
IF SWALLOWED, GET MEDICAL HELP OR CONTACT A POISON CONTROL CENTER RIGHT AWAY. 1-800-222-1222
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
TEMPORARILY PROTECTS MINOR:
- CUTS
- SCRAPES
- BURNS
- TEMPORARILY PROTECTS AND HELPS RELIEVE CHAPPED OR CRACKED SKIN AND LIPS
- HELPS PROTECT FROM THE DRYING EFFECTS OF WIND AND COLD WEATHER
History
There is currently no drug history available for this drug.
Other Information
There are no additional details available for this product.
Sources
Little Ones Petroleum Manufacturers
- Kmart Corporation
Little Ones Petroleum | Hamamatsu/queen’s Pet Imaging Center, Llc
The recommended dose of Fludeoxyglucose F 18 Injection for an adult (70 kg) is 185-370 MBq (5-10 mCi), as an intravenous injection for studies of malignancy, cardiology, and epilepsy.
In general, Fludeoxyglucose F 18 Injection should be administered after patients have fasted for 4-6 hours. For cardiac use, Fludeoxyglucose F 18 Injection may be administered either to patients who have fasted or to patients who have received a glucose load (See Patient Preparation section).
The optimum rates of administration and upper safe dose for Fludeoxyglucose F 18 Injection have not been established. The time interval between doses of Fludeoxyglucose F 18 Injection should be long enough to allow substantial decay (physical and biological) of previous administrations.
The final dose for the patient should be calculated using proper decay factors from the time of the end of synthesis (EOS), and measured by a suitable radioactivity calibration system before administration. See decay factors in Table 3.
Patient Preparation: Blood glucose levels should be stabilized before Fludeoxyglucose F 18 Injection is administered. In non-diabetic patients this may be accomplished by fasting 4-6 hours before Fludeoxyglucose F 18 Injection. Diabetic patients may need stabilization of blood glucose on the day preceding and on the day of administration of Fludeoxyglucose F 18 Injection.
For cardiac imaging, administration of Fludeoxyglucose F 18 Injection to fasting patients limits the accumulation of Fludeoxyglucose F 18 to ischemic myocardium. This may make localization of the ischemic region difficult because the surrounding myocardium will not be well visualized. Conversely, administration of Fludeoxyglucose F 18 Injection to patients who have received a glucose load (e.g., 50-75 grams, 1-2 hours before administration of Fludeoxyglucose F 18 Injection) allows the surrounding, non-ischemic myocardium to be seen and facilitates localization of ischemic areas.
Imaging: Optimally, it is recommended that positron emission tomography (PET) imaging be initiated within 40 minutes of administration of Fludeoxyglucose F 18 Injection.
Static emission scans are acquired 30-100 minutes from time of injection.
- Kmart Corporation
Login To Your Free Account